

IN THE DRAWINGS

The attached sheets of drawings includes changes to Figs. 1-5. These sheets, which include Figs. 1-5, replace the original sheets including Fig. 1-5.

Attachment: Replacement Sheets (5)

REMARKS

Favorable reconsideration of this application is respectfully requested in view of the above amendments and the following remarks.

Claims 1 and 3-21 are pending in this application. By this amendment, Claims 1 and 3-21 have been amended; and Claim 2 has been canceled. The subject matter of canceled Claim 2 has been incorporated into independent Claims 1 and 12. Other amendments have been made to the claims to place them in a preferred form for U.S. practice and/or to comply with objections made in the Office Action. Accordingly, it is respectfully submitted that no new matter has been added.

In the outstanding Office Action, the drawings were objected to under 37 C.F.R. § 1.83(a); the specification was objected to; the Examiner requested clarification regarding the claim for priority; Claim 1 was rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement; Claims 1, 2 and 11 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite; the Examiner made a finding with regard to Claim 12 invoking 35 U.S.C. § 112, sixth paragraph; and Claims 1-21 were rejected under 35 U.S.C. § 103(a) as being unpatentable over Møller et al. (Occurrence of Different Cancers in Patients with Parkinson's Disease, BMJ Vol. 310, June 10, 1995, hereinafter Møller) in view of Flagg (U.S. 6,456,979 B1).

In the objection to the drawings, the Examiner states "the subject matter in Claims 1 or 12 must be shown" without providing a further explanation regarding which features of those claims are asserted as not being shown in the drawings. Furthermore, the Examiner requests such drawings be labeled in text rather than numbers for clarification and

understandability. In response, each of the elements in the drawings will be labeled with the appropriate label. For example, Element 1 in FIG. 1 will be labeled "Analysis Module".

Based upon the corrections to the drawings, it is respectfully submitted that support for the elements recited in Claims 1 and 12 are shown therein. Accordingly, it is respectfully requested that this objection be reconsidered and withdrawn.

Responsive to the objection to the specification, the appropriate section headings have been incorporated by amendment. Accordingly, it is respectfully requested that this objection be reconsidered and withdrawn.

Responsive to the request for clarification regarding the claim for priority, the specification has been amended at the beginning thereof to include references to the priority documents. It should be noted that the corresponding PCT application is a continuation-in-part of priority document U.S. Application Serial No. 10/816,120. Therefore, it is expected that there will be differences in the descriptions between the instant application and the U.S. priority document. It is respectfully submitted that there is no requirement under 35 U.S.C. § 116 that the descriptions of the application and the priority document upon which the application is based be identical. Accordingly, it is respectfully requested that the claim for priority be appropriately acknowledged.

The rejection of Claim 1 under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement is respectfully traversed. The terminology used in Claim 1 is consistent with the terminology used in the specification and as shown in the corrected drawings to be subsequently filed. It is respectfully submitted that the term "module" is used in many patent applications and issued patents. It is further respectfully submitted that the

use of a broad term does not render claims indefinite or unenabled. It is therefore requested that this rejection be reconsidered and withdrawn.

Responsive to the rejection of Claims 1, 2 and 11 under 35 U.S.C. § 112, second paragraph, as indefinite, the term “and/or” has been amended to “or”, and the term “typical” has been deleted from Claim 2. Accordingly, it is respectfully requested that these rejections be reconsidered and withdrawn.

Responsive to the assertion in the Office Action that the “means for” language in Claim 12 invokes 35 U.S.C. § 112, sixth paragraph, Claim 12 and the claims dependent thereon have been amended to now recite “a device configured to”. Based thereon, it is respectfully submitted that Claim 12 and the claims dependent thereon do not invoke 35 U.S.C. § 112, sixth paragraph. Therefore, it is respectfully requested that this assertion be reconsidered and withdrawn.

Møller is a pure scientific study on the objective to observe the occurrence of cancer in a large cohort of patients with Parkinson’s disease based on three computerized registers in Denmark (hospital discharge register, cancer registry and register of deaths). The study tries to show correlation of risks, in this case the risk for Parkinson’s disease with different types of cancers and is based on simple data filtering, which can also be performed manually.

Møller does not show any automated system or application thereon.

In contrast to Møller, Flagg describes the use of databases or the use of adapted server software in the field of life insurance which software can deal with data of databases (database 250, FIG. 12 and column 23, lines 22-35). However, Flagg does not describe the realization of a system, as recited in the claims of the present application.


In consideration of the above, it is respectfully submitted that Claims 1 and 12, including the subject matter of Claim 2, patentably define over Møller, Flagg, or the combination thereof.

It is respectfully submitted that Claims 3-11 and 13-21 are patentable at least for the reasons argued above with regard to the claims from which they depend.

Accordingly, it is respectfully requested that the above-listed objections and rejections be reconsidered and withdrawn, and that Claims 1 and 3-21 be passed to allowance.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, L.L.P.



James J. Kulbaski  
Attorney of Record  
Registration No. 34,648

Jonathan W. Parthum  
Registration No. 64,082

Customer Number

**22850**

Tel: (703) 413-3000  
Fax: (703) 413-2220  
(OSMMN 08/09)